Patents by Inventor Rachel A. BURGA

Rachel A. BURGA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER
    Publication number: 20240226158
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: November 3, 2023
    Publication date: July 11, 2024
    Applicant: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
  • ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER
    Publication number: 20240131069
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: November 2, 2023
    Publication date: April 25, 2024
    Applicant: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
  • TUMOR-INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 AND USES THEREOF
    Publication number: 20240108722
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using arapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: January 18, 2022
    Publication date: April 4, 2024
    Applicant: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Kyle Pedro, James Alexander Storer, Jan ter Meulen, Rachel Burga, Mithun Khattar, Michelle Ols, Jeremy Tchaicha, Shyamsundar Subramanian
  • Functionalized Prussian blue nanoparticles, combination Prussian blue nanoparticle-based nano-immunotherapy and applications thereof
    Patent number: 11931465
    Abstract: Combination treatment with Prussian blue nanoparticles and at least one immunotherapeutic treatment. Stable, functionalized Prussian blue nanoparticles, including those with enhanced stability under alkaline conditions, and methods of cancer, neoplasm, and tumor treatment using them, including photothermal treatment and combination immunotherapeutic treatments.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 19, 2024
    Assignee: Children's National Medical Center
    Inventors: Rohan Fernandes, Raymond W. Sze, Conrad Russell Y. Cruz, Anthony D. Sandler, Catherine M. Bollard, Elizabeth E. Sweeney, Juliana Cano-Mejia, Rachel Burga, Matthieu F. Dumont
  • MODIFIED NATURAL KILLER CELLS AND METHODS OF USING THE SAME
    Publication number: 20230210897
    Abstract: The disclosure provides modified NK cells and pharmaceutical compositions comrpsing the same. The disclosure also provides methods of treating cancer using the same.
    Type: Application
    Filed: July 12, 2019
    Publication date: July 6, 2023
    Applicants: CHILDREN’S NATIONAL MEDICAL CENTER, THE GEORGE WASHINGTON UNIVERSITY
    Inventors: Catherine Mary BOLLARD, Conrad Russell Y. CRUZ, Rachel A. BURGA, Eric YVON
  • ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER
    Publication number: 20220133801
    Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
  • FUNCTIONALIZED PRUSSIAN BLUE NANOPARTICLES, COMBINATION PRUSSIAN BLUE NANOPARTICLE-BASED NANO-IMMUNOTHERAPY AND APPLICATIONS THEREOF
    Publication number: 20200163899
    Abstract: Combination treatment with Prussian blue nanoparticles and at least one immunotherapeutic treatment. Stable, functionalized Prussian blue nanoparticles, including those with enhanced stability under alkaline conditions, and methods of cancer, neoplasm, and tumor treatment using them, including photothermal treatment and combination immunotherapeutic treatments.
    Type: Application
    Filed: March 8, 2017
    Publication date: May 28, 2020
    Applicant: Children's National Medical Center
    Inventors: Rohan FERNANDES, Raymond W. SZE, Conrad Russell Y. CRUZ, Anthony D. SANDLER, Catherine M. BOLLARD, Elizabeth E. SWEENEY, Juliana CANO-MEJIA, Rachel BURGA, Mathieu F. DUMONT